QSAM Biosciences, Inc.
QSAM · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $372,938,000 |
| Gross Profit | $0 | $0 | $0 | -$372,938,000 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,160 | $1,022 | $647 | $362 |
| G&A Expenses | $2 | $4,439 | $10,394 | $962 |
| SG&A Expenses | $2,783 | $4,439 | $10,394 | $962 |
| Sales & Mktg Exp. | -$1,780,810,217 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$3,170 |
| Operating Expenses | $3,943 | $5,461 | $11,041 | $1,324 |
| Operating Income | -$3,943 | -$5,461 | -$11,041 | -$1,324 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$451 | -$20 | -$936 | -$4,496 |
| Pre-Tax Income | -$4,393 | -$5,481 | -$11,977 | -$5,820 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,393 | -$6,075 | -$12,766 | -$5,353 |
| % Margin | – | – | – | – |
| EPS | -1.24 | -3.45 | -16.13 | -19.57 |
| % Growth | 64.1% | 78.6% | 17.6% | – |
| EPS Diluted | -1.24 | -3.45 | -16.13 | -19.57 |
| Weighted Avg Shares Out | 3,531 | 1,762 | 792 | 273 |
| Weighted Avg Shares Out Dil | 3,531 | 1,762 | 792 | 273 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $53 | $74 | $789 | $490 |
| Depreciation & Amortization | $36,300,000 | $36 | $237 | -$3,170 |
| EBITDA | $36,295,660 | -$5,371 | -$11,696 | -$5,330 |
| % Margin | – | – | – | – |